Colgate-Palmolive (India) Ltd on Tuesday reported a profit of Rs 322.78 crore during the fiscal third quarter, recording a drop of 2.22 per cent in comparison to Rs 330.11 crore during the same period of previous financial year. It posted revenue from operations at Rs 1461.84 crore, up 4.74 per cent as against Rs 1395.65 crore during the third quarter of FY24. The company EBITDA stood at Rs 454.3 crore.
The company reported net sales of Rs 1452 crore for the quarter ended December 31, 2024, posting a growth of 4.7 per cent year-on-year. For the nine months, Colgate-Palmolive delivered net sales growth of 9.2 per cent year-on-year at Rs 4547 crore as compared to Rs 4164 crore for the same period last year. In a regulatory filing, the company said that the gross margin & EBITDA margin showed sequential improvement over the previous quarter, while down from last year’s high base.
Also ReadCoca-Cola recalls drinks across 6 European countries over chemical contamination concerns
Colgate-Palmolive recorded domestic growth of 3.2 per cent in Q3 and 8.8 per cent in 9MFY25.
Also Read ACC Q3 Results: Profit surges by 103.06% to Rs 1,091.79 crore, posts volume growth of 21% YoY Zee Q3 profit jumps 180%; revenue falls HDFC Bank Q3 Results: Profit rises by 2.22% to Rs 16,735.50 crore, NII at Rs 30,653 crore, beats estimates Kotak Mahindra Bank Q3 Results: Profit rises by 10.23% YoY to Rs 4701.02 crore, NII at Rs 7196 crore
For the nine months, Net profit after tax was recorded at Rs 1081.8 crore as compared to Rs 943.8 crore, up 14.6 per cent year-on-year.
Prabha Narasimhan, Managing Director & CEO, Colgate-Palmolive (India) Limited, said, “This has been a quarter of relatively soft demand, particularly in the urban market. In these market conditions and a heightened competitive landscape, we delivered a resilient performance this quarter with Toothpaste reporting mid-single digit intrinsic volume growth and continued competitive growth on toothbrushes. We continue to see positive momentum in our premium portfolio, driven by science-backed innovations. Margin profile continues to remain healthy. While the near term macro environment continues to look challenging, we are committed to driving growth through focus on a strategy that is working.”
» Read More
